Monday, November 21, 2016

News: Anika Reports Third Quarter 2016 Financial Results

BEDFORD, Mass.--()--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the third quarter ended September 30, 2016, along with business progress in the period.
“We continued to deliver solid financial results in the third quarter, while expanding globally and advancing our deep and differentiated pipeline to drive sustained growth”
Tweet this
“We continued to deliver solid financial results in the third quarter, while expanding globally and advancing our deep and differentiated pipeline to drive sustained growth,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “Last quarter, we had a productive meeting with the FDA regarding the CINGAL regulatory submission and continue to gain alignment on additional clinical and non-clinical work required to bring this important treatment to the U.S. Our confidence in the future success of CINGAL in the U.S. has been reaffirmed by how well CINGAL has been received by physicians in Canada and Europe, where we recently launched. We are well-positioned to achieve our operational and financial objectives for 2016 and to create significant near- and long-term value for patients and shareholders.”
Third Quarter Financial Results
  • Total revenue for the third quarter of 2016 increased 9% to $25.8 million, compared to $23.7 million for the third quarter of 2015.
  • Worldwide Orthobiologics revenue grew 10% year-over-year in the third quarter of 2016. MONOVISC revenue increased 33% year-over-year in the third quarter of 2016, and it was the Company’s main revenue growth driver during the period.
  • International Orthobiologics revenue grew 27% year-over-year in the first nine months of 2016 as a result of the Company’s global commercial expansion efforts. Domestically, we believe ORTHOVISC maintained its position as the leading multiple-injection product while MONOVISC continued to hold the number two position in the single-injection segment.
  • Total operating expenses for the third quarter of 2016 were $12.1 million, compared to $10.5 million for the third quarter of 2015, commensurate with the Company’s growth in revenue, increased commercial efforts, and active pipeline.
  • Net income for the third quarter of 2016 increased $0.6 million to $9.0 million, or $0.59 per diluted share, compared to $8.4 million, or $0.55 per diluted share, for the third quarter of 2015.
Recent Business Highlights
The Company made key commercial, operational, pipeline, and financial advancements, including:
  • Meeting with the U.S. Food and Drug Administration (FDA) in late September about the New Drug Application (NDA) for CINGAL, during which the Company and FDA aligned on one additional Phase III clinical trial to supplement the strong stable of existing pivotal data.
  • Advancing its product pipeline with continued progress on enrolling patients in the FastTRACK Phase III HYALOFAST Study for cartilage repair, as well as the Phase III MONOVISC study for the treatment of osteoarthritis pain in the hip.
  • Showcasing data from four recent studies evaluating the clinical utility of our HA-based bioscaffold, HYALOFAST, at the 13thWorld Congress of the International Cartilage Repair Society (ICRS).
  • Completing the Company’s $25 million accelerated share repurchase program, with a total of 531,067 shares repurchased by Anika.
  • Progressing with the consolidation of the Company’s global manufacturing operations at Anika’s Bedford, Mass. global headquarters.
Conference Call Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights tomorrow, Thursday, October 27th at 9:00 am ET. The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation may also be accessed via the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the last sentence of the second paragraph of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s future growth and creation of value, and the Company’s ability and positioning to meet its 2016 financial and operational goals. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (x) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission (SEC), and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
          
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2016201520162015
Product revenue$25,783$23,676$74,636$62,089
Licensing, milestone and contract revenue 6 5 17 16
Total revenue25,78923,68174,65362,105
 
Operating expenses:
Cost of product revenue4,9985,17616,48814,764
Research & development2,8222,0617,7735,971
Selling, general & administrative 4,280 3,309 12,525 10,302
Total operating expenses 12,100 10,546 36,786 31,037
Income from operations13,68913,13537,86731,068
Interest income, net 93 34 214 82
Income before income taxes13,78213,16938,08131,150
Provision for income taxes 4,830 4,789 13,619 11,435
Net income$8,952$8,380$24,462$19,715
 
Basic net income per share:
Net income$0.61$0.56$1.66$1.32
Basic weighted average common shares outstanding14,62514,96714,72614,945
Diluted net income per share:
Net income$0.59$0.55$1.61$1.29
Diluted weighted average common shares outstanding15,07715,31615,16315,311
 
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share data and per share data)
(unaudited)
   
September 30,December 31,
ASSETS20162015
Current assets:
Cash and cash equivalents$98,047$110,707
Investments22,25027,751
Accounts receivable, net of reserves of $224 and $167 at September 30, 2016 and December 31, 2015, respectively21,83321,652
Inventories18,02014,938
Prepaid expenses and other current assets 924  1,385 
Total current assets161,074176,433
Property and equipment, net51,05840,108
Long-term deposits and other6969
Intangible assets, net11,17111,656
Goodwill 7,690  7,482 
Total Assets$231,062 $235,748 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$1,949$8,302
Accrued expenses and other current liabilities5,4234,778
Income taxes payable 217  4,198 
Total current liabilities 7,589  17,278 
Other long-term liabilities2,556781
Long-term deferred revenue5966
Deferred tax liability6,3156,775
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively--
Common stock, $.01 par value; 60,000,000 and 30,000,000 shares authorized, 14,623,225 and 15,036,808 shares issued and outstanding at September30, 2016 and December 31, 2015, respectively146150
Additional paid-in-capital60,37481,685
Accumulated other comprehensive loss(6,101)(6,649)
Retained earnings 160,124  135,662 
Total stockholders’ equity 214,543  210,848 
Total Liabilities and Stockholders’ Equity$231,062 $235,748 
 
Anika Therapeutics, Inc. and Subsidiaries
Supplemental Financial Data
               
 
Revenue by Product Line and Product Gross Margin
(in thousands, except percentages)
(unaudited)
 
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2016 %2015 %2016 %2015 %
Orthobiologics$22,42887%$20,46186%$65,31988%$51,71783%
Surgical1,1735%1,4136%3,9245%4,4507%
Dermal5942%4122%1,5582%1,1322%
Other 1,588 6% 1,390 6% 3,835 5% 4,790 8%
Product Revenue$25,783 100%$23,676 100%$74,636 100%$62,089 100%
 
Product Gross Profit$20,785$18,500$58,148$47,325
Product Gross Margin
81%

78%

78%

76%

 
Product Revenue by Geographic Region
(in thousands, except percentages)
(unaudited)
                
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2016 %2015 
%
2016 
%
2015
 
%
Geographic Location:
United States$21,12682%$19,23982%$61,03282%$51,04882%
Europe2,70310%1,9778%8,24011%6,29410%
Other 1,954 8% 2,460 10% 5,364 7% 4,747 8%
Product Revenue$25,783 100%$23,676 100%$74,636 100%$62,089 100%
 

Contacts

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., President and CEO
or
Sylvia Cheung, CFO
781-457-9000
Published at BusinessWire